PMID- 38158895
OWN - NLM
STAT- MEDLINE
DCOM- 20240103
LR  - 20240106
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 95
IP  - 8
DP  - 2023 Oct 11
TI  - [Particularities of arterial stiffness dynamics on the background of breast 
      cancer chemotherapy].
PG  - 621-626
LID - 10.26442/00403660.2023.08.202327 [doi]
AB  - BACKGROUND: Modern breast cancer chemotherapy regimens (BC) consider individual 
      patient parameters and ranges of cardiotoxic doses. However, clinicians often 
      record clinical and laboratory-instrumental signs of cardio- and vasculotoxicity 
      in patients, which emphasizes the high importance of searching for markers of 
      early toxic response. AIM: To study the characteristics of the response of 
      arterial stiffness on the background of anthracycline-containing chemotherapy to 
      determine potential markers of vasculotoxicity in BC patients. MATERIALS AND 
      METHODS: 20 women with a BC were included. The patients received 4 cycles of 
      chemotherapy in the doxorubicin + cyclophosphane (AC) regimen with an interval of 
      2-3 weeks, then they were injected with paclitaxel weekly for 12 injections, or 
      docetaxel once every 3 weeks. All patients underwent TTE, arterial stiffness 
      determination by the "gold standard" method and using volumetric sphygmography 
      before the start of treatment, after the completion of the anthracycline 
      component and after the end of taxanes. RESULTS: The average age of the patients 
      was 45.5+/-5.31 years. After completing the course of anthracyclines, there was a 
      significant increase in heart rate (from 65.6+/-9.3 to 73.3+/-10.1 beats/min.), a 
      decrease in SBP (from 122.6+/-9.9 to 116.5+/-12.3 mmHg) and DBP (from 78.9+/-8.5 to 
      76.2+/-8.6 mmHg), a decrease in carotid femoral pulse wave velocity (cfPWV) (from 
      9.32+/-1.41 to 7.85+/-1.57 m/s), CAVI index on the left (from 6.78+/-0.81 to 6.5+/-0.88), 
      the velocity of the cardio-ankle pulse wave on the right and left (from 6.7+/-0.6 
      to 6.5+/-0.7 m/s; from 7.0+/-0.6 to 6.3+/-0.8 m/sc, respectively). After the completion 
      of the taxane, there was a tendency to increase these indicators, however, they 
      remained significantly lower compared to the values before the start of 
      treatment. CONCLUSION: A comparative analysis of arterial stiffness indicators at 
      different stages of chemotherapy showed a more pronounced reaction of cfPWV, 
      CAVI, cardio-ankle pulse wave to the administration of anthracyclines, which 
      presumably may be associated with concomitant hemodynamic restructuring.
FAU - Yushchuk, E N
AU  - Yushchuk EN
AUID- ORCID: 0000-0003-0065-5624
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
FAU - Medvedeva, E G
AU  - Medvedeva EG
AUID- ORCID: 0000-0002-5011-5346
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
FAU - Filonenko, D A
AU  - Filonenko DA
AUID- ORCID: 0000-0002-7224-3111
AD  - Loginov Moscow Clinical Scientific and Practical Center.
FAU - Ivanova, S V
AU  - Ivanova SV
AUID- ORCID: 0000-0001-7370-9297
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
FAU - Zhukova, L G
AU  - Zhukova LG
AUID- ORCID: 0000-0003-4848-6938
AD  - Loginov Moscow Clinical Scientific and Practical Center.
FAU - Sapunova, D A
AU  - Sapunova DA
AUID- ORCID: 0000-0001-7847-4693
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
LA  - rus
PT  - English Abstract
PT  - Journal Article
DEP - 20231011
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Anthracyclines)
SB  - IM
MH  - Humans
MH  - Female
MH  - Adult
MH  - Middle Aged
MH  - *Breast Neoplasms/drug therapy/chemically induced
MH  - Pulse Wave Analysis
MH  - *Vascular Stiffness
MH  - Cyclophosphamide/therapeutic use
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - Anthracyclines/adverse effects
OTO - NOTNLM
OT  - CAVI
OT  - arterial stiffness
OT  - breast cancer
OT  - pulse wave velocity
OT  - vascular toxicity
EDAT- 2024/01/02 11:42
MHDA- 2024/01/03 09:42
CRDT- 2023/12/30 07:53
PHST- 2023/10/08 00:00 [received]
PHST- 2023/10/08 00:00 [accepted]
PHST- 2024/01/03 09:42 [medline]
PHST- 2024/01/02 11:42 [pubmed]
PHST- 2023/12/30 07:53 [entrez]
AID - 10.26442/00403660.2023.08.202327 [doi]
PST - epublish
SO  - Ter Arkh. 2023 Oct 11;95(8):621-626. doi: 10.26442/00403660.2023.08.202327.